Pharmacological Basis of CD101 Efficacy: Exposure Shape Matters
暂无分享,去创建一个
Paul G. Ambrose | D. Andes | S. Bhavnani | P. Ambrose | K. Bartizal | A. Lepak | Lynn Miesel | Elizabeth A. Lakota | Justin C. Bader | Voon Ong | Ken Bartizal | David R. Andes | Sujata M. Bhavnani | Christopher M. Rubino | Alexander J. Lepak | E. Lakota | C. Rubino | L. Miesel | J. Bader | V. Ong
[1] Ronald N. Jones,et al. Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates , 2016, The Journal of antimicrobial chemotherapy.
[2] G. Drusano,et al. Once-Weekly Micafungin Therapy Is as Effective as Daily Therapy for Disseminated Candidiasis in Mice with Persistent Neutropenia , 2006, Antimicrobial Agents and Chemotherapy.
[3] J. Balkovec,et al. Preclinical Evaluation of the Stability, Safety, and Efficacy of CD101, a Novel Echinocandin , 2016, Antimicrobial Agents and Chemotherapy.
[4] T. Gumbo. Single or 2-Dose Micafungin Regimen for Treatment of Invasive Candidiasis: Therapia Sterilisans Magna! , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[5] M. Wasilewski,et al. Comparison of the Efficacy and Safety of Oritavancin Front-Loaded Dosing Regimens to Daily Dosing: an Analysis of the SIMPLIFI Trial , 2011, Antimicrobial Agents and Chemotherapy.
[6] R. Drew,et al. Echinocandin pharmacodynamics: review and clinical implications. , 2010, The Journal of antimicrobial chemotherapy.
[7] K. Bartizal,et al. Efficacy of CD101, a Novel Echinocandin, in Mouse Models of Aspergillosis and Azole-Resistant Disseminated Candidiasis , 2016 .
[8] G. Drusano,et al. In vivo activity of oritavancin in animal infection models and rationale for a new dosing regimen in humans. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[9] G. Drusano,et al. Pharmacokinetic-pharmacodynamic considerations in the design of hospital-acquired or ventilator-associated bacterial pneumonia studies: look before you leap! , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[10] K. D. James,et al. Pharmacokinetics of the Novel Echinocandin CD101 in Multiple Animal Species , 2017, Antimicrobial Agents and Chemotherapy.
[11] M. Pfaller,et al. In Vivo Pharmacodynamic Characterization of Anidulafungin in a Neutropenic Murine Candidiasis Model , 2007, Antimicrobial Agents and Chemotherapy.
[12] G. Moeck,et al. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium. , 2009, The Journal of antimicrobial chemotherapy.
[13] Clinical,et al. Reference method for broth dilution antifungal susceptibility testing of yeasts : Approved standard , 2008 .
[14] D. Thye,et al. Safety and Pharmacokinetics of CD101 IV, a Novel Echinocandin, in Healthy Adults , 2016, Antimicrobial Agents and Chemotherapy.
[15] George L. Drusano,et al. Pharmacodynamics of Caspofungin in a Murine Model of Systemic Candidiasis: Importance of Persistence of Caspofungin in Tissues to Understanding Drug Activity , 2005, Antimicrobial Agents and Chemotherapy.